DE60043620D1 - Mage-a1 peptide die von klasse ii hla molekule presentiert werden - Google Patents

Mage-a1 peptide die von klasse ii hla molekule presentiert werden

Info

Publication number
DE60043620D1
DE60043620D1 DE60043620T DE60043620T DE60043620D1 DE 60043620 D1 DE60043620 D1 DE 60043620D1 DE 60043620 T DE60043620 T DE 60043620T DE 60043620 T DE60043620 T DE 60043620T DE 60043620 D1 DE60043620 D1 DE 60043620D1
Authority
DE
Germany
Prior art keywords
mage
class
hla molecule
peptides presented
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043620T
Other languages
English (en)
Inventor
Snick Jacques Van
Bernard Lethe
Pascal Chaux
Thierry Boon-Falleur
Der Bruggen Pierre Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of DE60043620D1 publication Critical patent/DE60043620D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60043620T 1999-06-18 2000-06-14 Mage-a1 peptide die von klasse ii hla molekule presentiert werden Expired - Lifetime DE60043620D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/336,091 US7157091B1 (en) 1999-06-18 1999-06-18 MAGE-A1 peptides presented by HLA class II molecules
PCT/US2000/016287 WO2000078806A1 (en) 1999-06-18 2000-06-14 Mage-a1 peptides presented by hla class ii molecules

Publications (1)

Publication Number Publication Date
DE60043620D1 true DE60043620D1 (de) 2010-02-11

Family

ID=23314524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043620T Expired - Lifetime DE60043620D1 (de) 1999-06-18 2000-06-14 Mage-a1 peptide die von klasse ii hla molekule presentiert werden

Country Status (9)

Country Link
US (1) US7157091B1 (de)
EP (1) EP1224216B1 (de)
JP (2) JP2003502079A (de)
KR (1) KR20020026461A (de)
CN (1) CN100354305C (de)
AT (1) ATE453665T1 (de)
AU (1) AU778449B2 (de)
DE (1) DE60043620D1 (de)
WO (1) WO2000078806A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
EP1390387A4 (de) * 2001-04-20 2004-12-08 Ludwig Inst Cancer Res Hodenkrebsantigene
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US7758892B1 (en) * 2004-05-20 2010-07-20 Boston Scientific Scimed, Inc. Medical devices having multiple layers
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
EA017420B9 (ru) * 2005-04-18 2013-03-29 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
ES2657480T3 (es) * 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB0905519D0 (en) * 2009-03-31 2009-05-13 Biofortuna Ltd Assay method and device
CN103957930A (zh) * 2011-08-31 2014-07-30 国立大学法人三重大学 癌症治疗用疫苗制剂
US9687538B2 (en) 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US11154597B2 (en) 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
HRP20211493T1 (hr) * 2016-04-08 2022-01-21 Adaptimmune Limited Receptori t stanica
CN106084042B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗MAGEA1的全分子IgG抗体及其应用
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
CA2168582A1 (en) 1993-08-06 1995-02-16 John D. Fikes Cloning and characterization of the complete mage-1 gene
US5585461A (en) 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
KR100547049B1 (ko) * 1996-10-10 2006-02-01 프로브 인터내쇼날 바이러스 감염증 치료를 위한 조성물 및 방법
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules

Also Published As

Publication number Publication date
AU5736700A (en) 2001-01-09
JP2003502079A (ja) 2003-01-21
WO2000078806A1 (en) 2000-12-28
ATE453665T1 (de) 2010-01-15
EP1224216B1 (de) 2009-12-30
KR20020026461A (ko) 2002-04-10
JP2008109928A (ja) 2008-05-15
AU778449B2 (en) 2004-12-02
US7157091B1 (en) 2007-01-02
CN100354305C (zh) 2007-12-12
JP4652390B2 (ja) 2011-03-16
EP1224216A1 (de) 2002-07-24
CN1357006A (zh) 2002-07-03

Similar Documents

Publication Publication Date Title
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
CY1117065T1 (el) Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BR0208183A (pt) Peptìdeo modificado por wt1
CY1108049T1 (el) Πεπτιδια με βαση την αλληλουχια της ανθρωπινης λακτοφερρινης και χρηση τους
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
FR2827866B1 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
SI2952521T1 (en) Peptides derived from human BPLP protein, polynucleotides encoding these peptides, and antibodies directed against these peptides
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE69840024D1 (de) Antimikrobielle Peptide, abstammend von Ubiquicidin
EA200100700A1 (ru) Гены и белки и их применение
IL142709A0 (en) Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
SE9800504D0 (sv) Novel peptide/protein, diagnostic reagent and kit for detection of rickettsiosis
DK0811068T3 (da) Humane DNase I varianter
GB2357507A (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
WO2002099379A3 (en) Breast homing peptides and methods of identifying same using aminopeptidase p
FR2808284B1 (fr) Souches mutantes capables de produire des proteines chimiquement diversifiees par incorporation d'acides amines non conventionnels
WO2004058812A3 (en) Ribose-phosphate pyrophosphokinase polypeptides and structures

Legal Events

Date Code Title Description
8364 No opposition during term of opposition